版本:
中国

BRIEF-Cormedix inc qtrly loss per share $0.19

May 10 Cormedix Inc:

* Cormedix Inc qtrly loss per share $0.19

* Says in discussion with FDA regarding possible prospective changes to lock-it 100 trial protocol

* Says anticipate exceeding our original enrollment target of 632 patients by Q4 of 2017

* Says to pursue additional partnerships designed to further expand ex-U.S. sales of Neutrolin and begin augmenting our commercial presence in Europe

* Says expect to develop and pursue FDA clearance for potential products by 510(K) pathway

* Qtrly net sales $39,559 versus $41,427

* Says our cash used in operations in Q1 2017 was $6.8 million, compared with $6.5 million in Q4 2016 Source text: [bit.ly/2r0X5ZO]

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐